EGFR (G719D)

EGFR · Variant type: point · HGVS: p.G719D

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Osimertinib	99.9%	0.1%	97.24
2	Neratinib	99.7%	0.3%	93.18
3	Mobocertinib	99.6%	0.4%	97.22
4	Canertinib	99.6%	0.4%	96.49
5	Lazertinib	99.5%	0.5%	97.47
6	Zanubrutinib	99.1%	0.9%	98.24
7	Lapatinib	98.7%	1.3%	99.25
8	Erlotinib	98.6%	1.4%	99.75
9	Ibrutinib	98.1%	1.9%	94.74
10	Afatinib	98.0%	2.0%	98.50
11	Dacomitinib	97.9%	2.1%	97.99
12	Gefitinib	97.3%	2.7%	99.25
13	Vandetanib	96.5%	3.5%	95.74
14	Defactinib	96.0%	4.0%	92.68
15	Bosutinib	95.1%	4.9%	87.22
16	Dasatinib	90.0%	10.0%	87.97
17	Pralsetinib	76.1%	23.9%	93.43
18	Alectinib	72.6%	27.4%	95.49
19	Brigatinib	65.7%	34.3%	82.96
20	Pacritinib	59.6%	40.4%	88.64
21	Pirtobrutinib	51.1%	48.9%	99.49
22	Ponatinib	44.5%	55.5%	78.23
23	Fostamatinib	44.1%	55.9%	96.74
24	Alpelisib	29.5%	70.5%	97.22
25	Gilteritinib	20.6%	79.4%	88.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Osimertinib	99.9%	99.1%	+0.8%
Neratinib	99.7%	100.0%	-0.3%
Mobocertinib	99.6%	100.0%	-0.4%
Canertinib	99.6%	98.4%	+1.2%
Lazertinib	99.5%	100.0%	-0.5%
Zanubrutinib	99.1%	88.2%	+10.9%
Lapatinib	98.7%	99.2%	-0.4%
Erlotinib	98.6%	99.4%	-0.8%
Ibrutinib	98.1%	99.3%	-1.3%
Afatinib	98.0%	100.0%	-1.9%
Dacomitinib	97.9%	99.8%	-1.9%
Gefitinib	97.3%	99.9%	-2.6%
Vandetanib	96.5%	99.3%	-2.8%
Defactinib	96.0%	94.6%	+1.4%
Bosutinib	95.1%	99.3%	-4.2%
Dasatinib	90.0%	97.9%	-7.9%
Pralsetinib	76.1%	99.1%	-23.0%
Alectinib	72.6%	—	—
Brigatinib	65.7%	98.5%	-32.7%
Pacritinib	59.6%	—	—
Pirtobrutinib	51.1%	—	—
Ponatinib	44.5%	—	—
Fostamatinib	44.1%	97.8%	-53.6%
Alpelisib	29.5%	—	—
Gilteritinib	20.6%	91.0%	-70.4%

Cancer	Organ	Source
glioma_central_nervous_system	Brain/CNS	ref
carcinoma_lung	Lung	ref
carcinoma_oesophagus	Stomach/Digestive Tract	ref
LGG-US	Brain/CNS	ref
LGG	Brain/CNS	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.8ms